Patients who received 2 mg or 4 mg of baricitinib maintained vIGA-AD scores through 68 weeks of treatment.
MD Net Guide® - May 2021
The presence of extra-intestinal manifestations in biologic-naïve anti-TNF patients with Crohn’s disease was a predictor of disease severity.
A new study compares patients self-reported outcomes after depot or daily sublingual buprenorphine treatment, including satisfaction and burden rates.
The majority of adverse effects reported were considered mild.
A new study presented at ASGCT found that patients with indications of hemostatic efficacy experienced few adverse effects with gene therapy treatment BAY 2599023.
Advertisement
Advertisement
Trending on HCPLive
1
Navigating Emotional Burden in IBD
2
Highlighting FDA-Approved Therapies in Atopic Dermatitis, With Chris Bunick, MD, PhD
3
Open Communication Between Patients and Providers in IBD
4
Linaclotide in Pediatric IBS-C—Evidence, Indications, and Practical Use
5